Drug profile · INN
timolol
TIMOPTOL
timolol (TIMOPTOL) is a beta-2 adrenergic receptor antagonist. Associated with Mundipharma Pty Limited. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — timolol
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
timolol (TIMOPTOL) is a beta-2 adrenergic receptor antagonist. Associated with Mundipharma Pty Limited. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is timolol?
timolol (TIMOPTOL) is a beta-2 adrenergic receptor antagonist. Associated with Mundipharma Pty Limited. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for timolol?
TIMOPTOL is a marketed brand name for timolol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of timolol?
timolol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.